Colorectal Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)

Doublet or triplet chemotherapy, alone or in combination with angiogenesis inhibitors, remains the cornerstone of treatment for metastatic colorectal cancer. Patients without RAS or BRAF mutations also benefit from EGFR inhibitors (Merck & Co. / Eli Lilly’s Erbitux and Amgen’s Vectibix), which are recommended for first-line treatment of patients with left-sided tumors. Additional targeted therapies have expanded treatment options for specific molecular subgroups, including immune checkpoint inhibitors (Merck & Co.’s Keytruda and Bristol Myers Squibb’s Opdivo and Yervoy) for MSI-high and/or dMMR tumors, BRAF inhibitors (Array BioPharma / Pfizer’s Braftovi) for BRAF V600E-mutated disease, KRAS G12C inhibitors (Bristol Myers Squibb’s Krazati and Amgen´s Lumakras) for KRAS G12C-mutated tumors, and HER2-targeting agents (Chugai’s Perjeta and trastuzumab and Seagen’s Tukysa), available in some markets for HER2-positive metastatic disease.

Late-phase development programs will further broaden the treatment landscape both in early-stage and metastatic colorectal cancer. In early-stage colon and rectal cancers, immune checkpoint inhibitors aim to expand the role of immunotherapy beyond the metastatic setting for MSI-high/dMMR tumors. In metastatic disease, key areas of investigation include therapies targeting MET and CEACAM5 expression, next-generation KRAS G12C inhibitors for KRAS G12C-mutated tumors, novel EGFR-directed therapies for RAS/BRAF wild-type disease, and immunotherapy-based approaches for MSS/pMMR disease.

Questions answered

• How large are the drug-treatable colorectal cancer populations? How do patient populations differ by disease stage and key biomarkers?
• What is the current treatment landscape in colorectal cancer? Which currently approved drugs are the most prescribed and why?
• Which are the most promising agents in the pipeline, and how will they shape the future of the colorectal cancer therapy market?
• What are the key drivers and constraints in the colorectal cancer therapy market, and how will they evolve over the forecast period?

Geography: United States, EU5, Japan

Primary research: Country-specific interviews with thought-leading medical oncologists; survey data collected for this and other Clarivate research

Epidemiology: Diagnosed and recurrent incidence of colorectal cancer; drug-treatable and -treated cases by country, disease stage, tumor side, BRAF status, and RAS status

Forecast: 10-year, annualized, drug-level sales and patient share of key colorectal cancer therapies through 2035, segmented by brands / generics and epidemiological subpopulations

Drug treatments: Coverage of key current and emerging therapies

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.